<p>MicroRNA-497-5p Induces Cell Cycle Arrest Of Cervical Cancer Cells In S Phase By Targeting CBX4</p>

Abstract

miR-497-5p can inhibit cervical cancer cell proliferation. However, the underlying mechanism remains to be elucidated. Methods: Bioinformatics was used to analyze the target genes of miR-497-5p. qRT-PCR and Western blot were used to analyze mRNA and protein expression, respectively. Dualluciferase reporter assay was used to analyze the direct binding between miR-497-5p and 3ʹ-untranslated region of CBX4. Cell viability was measured with MTT assay. Flow cytometry was performed to detect cell cycle distribution. Results: Here, using bioinformatics methods we firstly found that miR-497-5p regulated cervical carcinoma proliferation by targeting polycomb chromobox4 (CBX4). Expression of miR-497-5p in cervical carcinoma tissues was negatively correlated with CBX4. A binding region of miR-497-5p in 3ʹ-untranslated region of CBX4 was predicted. Further experiments confirmed that miR-497-5p directly targeted CBX4. Besides, RNA interference of CBX4 inhibited cervical cancer cell proliferation, arrested cells at S phase and reduced the expression of CDK2 and Cyclin A2 proteins. The use of miR-497-5p inhibitor compromised CBX4 interference RNAs induced cycle arrest of cervical cancer cells. Cells co-transfected with miR-497-5p inhibitors and CBX4 interference RNAs had a higher proliferation rate than CBX4 inference RNA-transfected cells. Conclusion: All together, the present study demonstrates that miR-497-5p inhibits cervical cancer cells proliferation by directly targeting CBX4.

circ_0084927 promotes cervical carcinogenesis by sponging miR-1179 that suppresses CDK2, a cell cycle-related gene

“…For instance, silencing CDK2 attenuated aerobic glycolytic cell metabolism in cells, thereby inhibiting the malignant characterization of gastric cancer cells [55]. CDK2 was also up-regulated in many cancers as a cell cycle-dependent kinase that contributed to cell cycle progression and DNA damage responses [56]. This up-regulation of CDK2 provided new immune targets for therapy on multiple cancers.…”

Regulation of microRNA‑497 expression in human cancer (Review)

“…cancer (44,45), thyroid cancer (46,47), cutaneous squamous cell carcinoma (48,49), melanoma (50), glioma (51), clear cell renal cell carcinoma (52), anaplastic large cell lymphoma (53), esophageal carcinoma (54) and bladder cancer (9), among others. These results suggest that miR-497 acts as a tumor suppressor.…”

“…Subsequently, a study of the global miRNA expression profile of gastric cancer was the first to demonstrate that the expression of miR-497 was increased in non-tumor tissues ( 12 ). Accumulating evidence shows that the expression of miR-497 is downregulated in several tumor types, including primary peritoneal carcinoma ( 13 ), adrenocortical carcinoma ( 14 , 15 ), malignant astrocytoma ( 16 ), colorectal cancer ( 17 – 21 ), osteosarcoma ( 22 ), cervical cancer ( 23 ), liver cancer ( 24 – 28 ), breast cancer ( 29 – 31 ), neuroblastoma ( 32 ), non-small cell lung cancer ( 33 – 35 ), gastric cancer ( 36 – 38 ), ovarian cancer ( 39 ), nasopharyngeal carcinoma ( 40 ), osteosarcoma ( 41 , 42 ), angiosarcoma ( 43 ), cervical cancer ( 44 , 45 ), thyroid cancer ( 46 , 47 ), cutaneous squamous cell carcinoma ( 48 , 49 ), melanoma ( 50 ), glioma ( 51 ), clear cell renal cell carcinoma ( 52 ), anaplastic large cell lymphoma ( 53 ), esophageal carcinoma ( 54 ) and bladder cancer ( 9 ), among others. These results suggest that miR-497 acts as a tumor suppressor.…”

Circ_0084927 promotes cervical carcinogenesis by sponging miR-1179 that suppresses CDK2, a cell cycle-related gene

“…We identified a novel regulatory interactome that might contribute to the comprehension of CC pathogenesis. What's more, CDK2 was up-regulated in many cancers as a cell cycle-dependent kinase that normally contributed to cell cycle progression and DNA damage responses [56]. This up-regulation of CDK2 provided new immune targets for therapy on multiple cancers, and the study of CDK2 inhibitors also provided new prospects for cancer treatment [57,58].…”